Juvenile Diabetes Research Foundation
232
15
29
168
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
7.8%
18 terminated/withdrawn out of 232 trials
90.3%
+3.8% vs industry average
9%
21 trials in Phase 3/4
49%
82 of 168 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (232)
The T1D Parent Check-In: A Preventative Intervention
Role: collaborator
Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM
Role: collaborator
Repurposing Colchicine for Reduction of Residual Inflammatory Risk in Type 1 Diabetes
Role: collaborator
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
Role: collaborator
MyDiaMate For Remission Of Diabetes Distress In Type 1 Diabetes (MyREMEDY)
Role: collaborator
ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2
Role: collaborator
Early Check: Expanded Screening in Newborns
Role: collaborator
Fenofibrate for Prevention of DR Worsening
Role: collaborator
Transdisciplinary Care for Young Adults With Type 1 Diabetes
Role: collaborator
TArgeting Type 1 Diabetes Using POLyamines (TADPOL)
Role: collaborator
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
Role: collaborator
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
Role: collaborator
Type 1 Diabetes, Exercise and Mentoring Trial
Role: collaborator
A Hybrid Effectiveness-implementation Trial to Reduce Diabetes Distress in Teenagers
Role: collaborator
Triple Therapy in T1DM
Role: collaborator
Verapamil SR in Adults With Type 1 Diabetes
Role: collaborator
Lactobacillus Johnsonii in Children and Adolescents With T1D
Role: collaborator
Diabetes Transition Coordinator Study
Role: collaborator
Immune Function and the Progression to T1D
Role: collaborator
Butyrate Adjuvant Therapy for Type 1 Diabetes
Role: collaborator